NASDAQ:DRIO DarioHealth (DRIO) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free DRIO Stock Alerts $1.48 +0.01 (+0.34%) (As of 02:34 PM ET) Add Compare Share Share Today's Range$1.45▼$1.5150-Day Range$1.14▼$2.4452-Week Range$0.68▼$4.58Volume46,607 shsAverage Volume133,392 shsMarket Capitalization$43.78 millionP/E RatioN/ADividend YieldN/APrice Target$5.37 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get DarioHealth alerts: Email Address DarioHealth MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside260.2% Upside$5.37 Price TargetShort InterestBearish4.65% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.20) to ($1.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.63 out of 5 starsMedical Sector663rd out of 908 stocksSurgical & Medical Instruments Industry74th out of 97 stocks 3.5 Analyst's Opinion Consensus RatingDarioHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDarioHealth has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.65% of the outstanding shares of DarioHealth have been sold short.Short Interest Ratio / Days to CoverDarioHealth has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in DarioHealth has recently increased by 1.47%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDarioHealth does not currently pay a dividend.Dividend GrowthDarioHealth does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DRIO. Previous Next 1.8 News and Social Media Coverage News SentimentDarioHealth has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for DarioHealth this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for DRIO on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added DarioHealth to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DarioHealth insiders have not sold or bought any company stock.Percentage Held by Insiders10.10% of the stock of DarioHealth is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.39% of the stock of DarioHealth is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for DarioHealth are expected to grow in the coming year, from ($2.20) to ($1.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DarioHealth is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DarioHealth is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDarioHealth has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About DarioHealth Stock (NASDAQ:DRIO)DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Read More DRIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRIO Stock News HeadlinesApril 25, 2024 | prnewswire.comDario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical OutcomesApril 22, 2024 | msn.comDarioHealth files to sell 15.73M shares for holdersApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? April 18, 2024 | prnewswire.comDario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 SolutionApril 17, 2024 | money.usnews.comDarioHealth CorpApril 10, 2024 | prnewswire.comDario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral HealthApril 3, 2024 | benzinga.comDarioHealth Stock (NASDAQ:DRIO), Analyst Ratings, Price Targets, PredictionsApril 2, 2024 | prnewswire.comTwo National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee HealthApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? April 1, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Staar Surgical (STAA), DarioHealth (DRIO) and Accelerate Diagnostics (AXDX)March 30, 2024 | seekingalpha.comDarioHealth Corp. (DRIO) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | finanznachrichten.deDarioHealth Corp.: DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating ResultsMarch 28, 2024 | markets.businessinsider.comDarioHealth earnings preview: what to expectMarch 28, 2024 | investorplace.comDRIO Stock Earnings: DarioHealth Beats EPS, Beats Revenue for Q4 2023March 28, 2024 | finance.yahoo.comDarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating ResultsMarch 21, 2024 | prnewswire.comDARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28THMarch 15, 2024 | finance.yahoo.comDRIO Apr 2024 5.000 putMarch 12, 2024 | prnewswire.comNew Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 MedicationsMarch 7, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: DarioHealth (DRIO), United Therapeutics (UTHR)February 28, 2024 | prnewswire.comDARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCEFebruary 28, 2024 | prnewswire.comDARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCEFebruary 21, 2024 | ca.finance.yahoo.comDarioHealth Corp. (DRIO)February 21, 2024 | tmcnet.comDario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditionsFebruary 21, 2024 | msn.comDario buys Twill to create digital health platform across most prevalent chronic conditionsFebruary 21, 2024 | prnewswire.comDario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditionsFebruary 6, 2024 | benzinga.comDarioHealth Stock (NASDAQ:DRIO), Short Interest ReportJanuary 18, 2024 | msn.comCano Health, DarioHealth among healthcare moversSee More Headlines Receive DRIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DarioHealth and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/26/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:DRIO CUSIPN/A CIK1533998 Webwww.mydario.com Phone(833) 914-3796Fax972-4770-4059Employees276Year Founded2011Price Target and Rating Average Stock Price Target$5.37 High Stock Price Target$8.00 Low Stock Price Target$4.00 Potential Upside/Downside+260.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,430,000.00 Net Margins-165.96% Pretax Margin-291.68% Return on Equity-48.84% Return on Assets-31.56% Debt Debt-to-Equity Ratio0.42 Current Ratio3.79 Quick Ratio3.38 Sales & Book Value Annual Sales$20.35 million Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book Value$2.14 per share Price / Book0.70Miscellaneous Outstanding Shares29,680,000Free Float26,679,000Market Cap$44.22 million OptionableOptionable Beta1.66 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Erez Raphael (Age 51)CEO & Director Comp: $722.19kMr. Richard A. Anderson (Age 55)President Comp: $536.65kMr. Zvi Ben David CPA (Age 63)CFO, Treasurer & Secretary Comp: $342.58kDov OppenheimCo-Founder & Production ChiefMr. Tomer Ben-Kiki (Age 53)Chief Operating Officer Josh FischerSenior Vice President of Operations & ComplianceClaudia LeviContent & Communications ManagerMary MooneyVice President of MarketingLimor DreznerChief People OfficerMr. Jean Christophe MuylHead of Commercialization North AmericaMore ExecutivesKey CompetitorsCarmellNASDAQ:CTCXBeyond AirNASDAQ:XAIRGBSNYSE:GBSApyx MedicalNASDAQ:APYXInspireMDNYSE:NSPRView All CompetitorsInstitutional OwnershipClarity Capital Partners LLCBought 170,426 shares on 2/20/2024Ownership: 0.626%Appian Way Asset Management LPBought 32,448 shares on 2/14/2024Ownership: 4.858%Clal Insurance Enterprises Holdings LtdSold 60,701 shares on 2/14/2024Ownership: 3.218%View All Institutional Transactions DRIO Stock Analysis - Frequently Asked Questions Should I buy or sell DarioHealth stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DRIO shares. View DRIO analyst ratings or view top-rated stocks. What is DarioHealth's stock price target for 2024? 2 Wall Street research analysts have issued 12 month target prices for DarioHealth's stock. Their DRIO share price targets range from $4.00 to $8.00. On average, they expect the company's share price to reach $5.37 in the next year. This suggests a possible upside of 260.2% from the stock's current price. View analysts price targets for DRIO or view top-rated stocks among Wall Street analysts. How have DRIO shares performed in 2024? DarioHealth's stock was trading at $1.72 at the beginning of 2024. Since then, DRIO stock has decreased by 13.4% and is now trading at $1.49. View the best growth stocks for 2024 here. When is DarioHealth's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our DRIO earnings forecast. How were DarioHealth's earnings last quarter? DarioHealth Corp. (NASDAQ:DRIO) released its quarterly earnings results on Thursday, March, 28th. The company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.13. The company had revenue of $3.62 million for the quarter, compared to the consensus estimate of $3.57 million. DarioHealth had a negative net margin of 165.96% and a negative trailing twelve-month return on equity of 48.84%. What other stocks do shareholders of DarioHealth own? Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL). How do I buy shares of DarioHealth? Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does DarioHealth have any subsidiaries? The following companies are subsidiares of DarioHealth: Labstyle Innovation Ltd., PsyInnovations Inc., PsyInnovations India Private Limited., Upright Technologies Inc., and Upright Technologies Ltd..Read More This page (NASDAQ:DRIO) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DarioHealth Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
